Protocol Ledger

NCT05405725 · Phase III · COMPLETED

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Interventional Phase III clinical trial protocol NCT05405725 sponsored by Enzene Biosciences in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-04 Enrollment: 504 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05405725
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)504 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05405725
Protocol FieldVerified Registry Value
NCT IdentifierNCT05405725
Consolidated Lead SponsorEnzene Biosciences
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment504 participants (ACTUAL)
Registered Start Date2022-07-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05405725
Hospital Research SiteLocationSite Profile
Fakultni nemocnice v MotolePrague, CzechiaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI